Benign Breast Lesions & Non-Malignant Breast Disease – Comprehensive Study Notes

Overview of Breast Anatomy & Physiology

• THREE key characteristics that differentiate the breast from other organs

  • $\bullet$ Primary function = post-natal nutrition & infant survival

  • $\bullet$ Life-long dynamic structural change

  • Puberty → lobular expansion

  • Adulthood → monthly remodeling, pregnancy-related proliferation, post-lactational regression

  • Involution & stromal fatty replacement after 3rd decade

  • $\bullet$ Unique social/cultural symbolism → impacts presentation & management

• Structural components and potential tumour sources

  • 2 major functional units: ducts & lobules (terminal-duct lobular units, TDLU)

  • 2 epithelial cell layers: luminal (secretory) & myoepithelial (contractile)

  • 2 stromal types: interlobular (dense, radiodense) & intralobular (specialised, hormonally responsive)

• Ductal system specifics

  • 6-10 major lactiferous ducts → branch → lobules

  • Superficial segments lined by keratinising squamous epithelium → abrupt transition to double-layered epithelium

  • Post-puberty: extensive TDLU development; some ducts may reach subcutaneous chest wall or axilla → ectopic disease sites

• Hormonal regulation & cyclical change

  • Follicular phase: lobular quiescence

  • Luteal phase: ↑estrogen/↑progesterone → ↑cell proliferation, ↑acini/TDLU

  • Menstruation: hormone fall → lobular apoptosis/regression

  • Pregnancy

  • Progressive lobular hyperplasia; near-total replacement of stroma by lobules by term

  • Early postpartum: colostrum (protein-rich) → mature milk (fat-rich) ~10 d; progesterone drop triggers switch

  • Post-lactational involution incomplete → persistent architectural change confers ↓breast-cancer risk when parity is early

• Age-related involution

  • Begins <35 y; lobules/stroma regress; fibrous interlobular stroma → radiolucent adipose

  • Obesity or exogenous HRT may delay involution

Clinical Presentations of Breast Disease

• 4 most frequent symptoms/signs (>90 % benign)

  1. Pain (mastalgia/mastodynia)

  • Cyclic (premenstrual oedema) vs non-cyclic (localised; cyst rupture, trauma, infection); 5 % associated with carcinoma

  1. Inflammation (erythema/oedema)

  • Rare; lactational infections predominant (S. aureus); must exclude inflammatory carcinoma (dermal lymphatic blockage)

  1. Nipple discharge

  • Normal: small, bilateral

  • Milky (galactorrhea): hyperprolactinaemia, hypothyroid, anovulation, drugs (OC, TCA, methyldopa, phenothiazine) or nipple stimulation

  • Bloody/serous: large-duct papilloma, cysts, pregnancy remodelling, DCIS (risk rises with age; unilateral, spontaneous, bloody in ≥60 y suggests malignancy)

  1. Palpable mass / “lumpiness”

  • Diffuse nodularity often normal tissue; imaging to exclude discrete lesion when pronounced

  • Discrete masses: benign (fibroadenoma, cyst) = mobile, rubbery, circumscribed; malignant = hard, irregular, infiltrative

  • Probability of malignancy by age: <40 y → ~10 %; >50 y → ~60 %

  • 50 % carcinomas in upper-outer quadrant; ⅓ first detected by palpation; most metastasise before palpability

• Imaging

  • Mammography: introduced 1980s; detects densities & calcifications

  • Sensitivity ↑ with age (40 y: 10 % positive predictive value → >25 % in ≥50 y)

  • Densities: benign (round; cyst, fibroadenoma) vs malignant (irregular)

  • Calcifications: benign apocrine cyst/fibroadenoma/sclerosing adenosis vs malignant (small, pleomorphic, clustered)

  • Ultrasonography: cystic vs solid; margin definition

  • MRI: detects ↑contrast uptake (neo-vascularity); helpful in dense breasts

• Screening limitations

  • Rapidly growing or pre-screen-age cancers evade detection

  • Overdiagnosis of indolent lesions (analogous to prostate cancer); need better prognostic biomarkers

Inflammatory Disorders (<1 % breast symptoms)

• General aetiologies: infection, autoimmune, foreign-body (keratin/secretions)

• Always rule out inflammatory carcinoma (tumour emboli occluding dermal lymphatics)

1. Acute Mastitis

• Timing: 1st month postpartum (nipple cracks/fissures)

• Pathogens: S. aureus (→ multiple abscesses) > Streptococci (→ cellulitis)

• Presentation: erythematous, painful sector; fever

• Rx: antibiotics + continued milk expression; rare surgical drainage

2. Squamous Metaplasia of Lactiferous Ducts (SMOLD)

• AKA: recurrent subareolar abscess, periductal mastitis, Zuska disease

• >90 % smokers; smoking/vit-A deficiency → squamous metaplasia of duct epithelium → keratin plug

• Duct rupture → intense granulocytic reaction → painful subareolar mass ± fistula

3. Duct Ectasia

• Multiparous women, 50–60 y; NOT linked to smoking

• Pathology: dilated large ducts, thick fibrous wall w/ elastosis; central foamy macrophages

• Clinical: periareolar pal­pable mass ± thick white discharge, skin/nipple retraction; mimics carcinoma on imaging/palpation

4. Fat Necrosis

• ~50 % post-trauma or surgery

• Presents as painless mass, skin retraction/thickening, or mammographic density/calcification; strong clinical mimic of malignancy

5. Lymphocytic Mastopathy (Sclerosing Lymphocytic Lobulitis)

• Autoimmune (often with type 1 DM or thyroiditis)

• Hard, palpable masses; dense keloid-like stroma with periductal/perivascular lymphocytes

6. Granulomatous Mastitis

• Numerous causes: sarcoid, Wegener, TB, fungal, idiopathic (Corynebacterium-related)

• Must culture/biopsy to exclude infection & systemic granulomatous disease

Benign Epithelial Lesions

Benign epithelial changes classified by cancer risk:

1. Non-proliferative (fibrocystic changes) – baseline risk

2. Proliferative without atypia – $1.5\text{–}2\times$ risk

3. Proliferative with atypia – $4\text{–}5\times$ risk (both breasts)
   Risk-reduction: bilateral prophylactic mastectomy or SERMs (tamoxifen); <20 % atypia patients develop carcinoma so surveillance often preferred.

1. Non-Proliferative (“Fibrocystic”) Changes

• Terminology varies by clinician vs radiologist vs pathologist

• Three morphologies (often co-existing)

  1. Cysts (blue-domed) ± apocrine metaplasia; luminal calcifications common

  2. Fibrosis (secondary to cyst rupture → chronic inflam & scarring)

  3. Adenosis (↑number of acini/TDLU); usually pregnancy-related or part of fibrocystic change

• Generally NO increased carcinoma risk, despite occasional clonality/genetic aberrations

2. Proliferative Disease WITHOUT Atypia

• Small but definite future-cancer risk; marker rather than precursor

• Detected via mammographic density/calcification or incidental

• Subtypes

  1. Epithelial hyperplasia (usual ductal hyperplasia)

  • TDLU lumen crowded by mixed luminal & myoepithelial cells; peripheral slit-like fenestrations

  1. Sclerosing adenosis

  • ↑acini compressed/distorted; palpable/radiologic mass; frequent calcification

  1. Complex sclerosing lesion (incl. radial scar)

  • Components of sclerosing adenosis + papilloma + hyperplasia; irregular stellate mass that mimics invasive carcinoma macroscopically & microscopically

  1. Papilloma (large-duct type)

  • Branching fibrovascular cores within dilated duct; nipple discharge (serous or bloody due to stalk torsion)

• Gynecomastia (male)

  • Only common benign male breast lesion; subareolar “button” enlargement, unilateral or bilateral

  • Histology: ductal epithelial hyperplasia + dense collagenous stroma; NO lobules

  • Pathogenesis: estrogen–androgen imbalance

  • Puberty, aging (↓androgens), liver cirrhosis, testicular tumours, Klinefelter (XXY), drugs (alcohol, marijuana, HAART, anabolic steroids, heroin)

3. Proliferative Disease WITH Atypia (Atypical Hyperplasia)

• Clonal lesions with partial features of carcinoma in situ

• Types & prevalence

  1. Atypical ductal hyperplasia (ADH) – 5-17 % of biopsies for calcifications

  2. Atypical lobular hyperplasia (ALH) – <5 % biopsies; incidental

• Biology: High ER expression, low Ki-67; some chromosomal gains/losses; ALH & LCIS share E-cadherin loss

Stromal Tumours

Two stromal compartments → distinct neoplasms

• Intralobular stroma – biphasic tumours (stromal neoplastic + benign epithelium) driven by $\text{MED12}$ mutations

  1. Fibroadenoma

  2. Phyllodes tumour

• Interlobular stroma – purely mesenchymal tumours similar to soft-tissue counterparts (lipoma, angiosarcoma, myofibroblastoma, fibromatosis)

1. Fibroadenoma

• Most common benign female breast tumour; 20-30s; often multiple & bilateral

• 2/3 harbour $\text{MED12}$ exon 2 mutations; hormonally responsive (↑ size pregnancy, ↓ menopause)

• Clinical

  • Mobile, painless, well-circumscribed “marble” (2–4 cm)

  • Rapid pregnancy growth ± infarction → mimic carcinoma

  • Cyclosporine A (post-renal transplant) → multiple bilateral lesions (regress post-cessation)

• Pathology

  • Gross: rubbery, white, whorled

  • Micro: intralobular stromal proliferation compresses epithelium → slit-like ducts

• Slight carcinoma risk, accentuated by “complex” features (large cysts >0.3 cm, sclerosing adenosis, calcifications, papillary apocrine change) – may reflect accompanying field defects (atypical hyperplasia nearby)

2. Lesions of Interlobular Stroma

• Pure stromal cell tumours; uncommon

  • Myofibroblastoma: occurs equally in males; benign

  • Lipoma: palpable or mammographic fat lesion

  • Fibromatosis: clonal fibroblasts/myofibroblasts; infiltrative; analogous to desmoid; associated with trauma, surgery, FAP (APC mutation) or Gardner syndrome; no metastasis but locally aggressive

  • Angiosarcoma: rare, high-grade malignant; may complicate chronic lymphedema or prior radiotherapy (not detailed in slides but relevant)

3. Phyllodes Tumour ("Cystosarcoma Phylloides")

• Biphasic, $\text{MED12}$-mutated; median age 45 y (later than fibroadenoma)

• Gross: rounded, well-circumscribed, firm; gray-white cut surface with cleft-like slit spaces (leaf-like architecture)

• Histologic hallmarks

  1. Stromal hypercellularity + atypia/mitoses grading (benign, borderline, malignant)

  2. Interspersed benign ductal elements

• Malignant phyllodes → marked atypia, numerous mitoses, loss of epithelial-stromal relationship; DDx: primary breast sarcoma, metaplastic carcinoma

• Benign forms must be separated from cellular fibroadenoma

• Treatment: wide excision; haematogenous metastasis if malignant

Disorders of Development

• Milk line remnants: persistent epidermal ridge anywhere axilla → groin → supernumerary nipples/breasts

• Accessory axillary breast tissue: failure of regression → palpable mass in axilla (can harbour carcinoma)

• Congenital nipple inversion: failure of nipple eversion; distinguish from acquired inversion (inflamm/neoplasm)

• Macromastia (gigantomastia): exaggerated hormonal response; may require reduction surgery

Numerical & Statistical Highlights

• >90 % symptomatic lesions benign; <10 % of painful masses = carcinoma

• Probability mammographic lesion is cancer: 40 y = 10 %; ≥50 y = >25 %

• Cancer detection: 45 % symptomatic vs 55 % screening

• Location distribution: 50 % upper-outer quadrant, ⅓ as palpable mass

• Risk multipliers

  • Proliferative without atypia: $1.5\text{–}2\times$

  • Proliferative with atypia: $4\text{–}5\times$

• Lobular carcinoma risk persists bilaterally after atypia; <20 % atypia progress

Integration & Clinical Implications

• Dynamic hormonal milieu underpins both physiologic change & pathogenesis; understanding cycle/pregnancy involution essential for interpreting imaging/pathology.

• MED12-driven stromal tumours (breast & uterine leiomyoma) suggest common stromal oncogenic pathway influenced by sex hormones.

• Smoking uniquely predisposes to SMOLD via vitamin-A mediated epithelial metaplasia – targeted prevention by smoking cessation.

• Imaging-pathology correlation vital: radial scar, fat necrosis, sclerosing adenosis, duct ectasia can all mimic carcinoma → mandatory core biopsy.

• Overdiagnosis underscores need for molecular prognostic signatures to triage indolent vs aggressive screen-detected cancers.

• Men with liver disease/drug exposure warrant evaluation for gynecomastia; persistent unilateral enlargement merits imaging to exclude male breast carcinoma.

Ethico-Social Note

“Breasts matter socially & culturally; however, patient-centred care requires focus on individual risk & management rather than societal perception.” (Slide 45 paraphrase)